Kollmar, Otto

[["dc.bibliographiccitation.firstpage","215"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes"],["dc.bibliographiccitation.lastpage","222"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Schäfer, T."],["dc.contributor.author","Sperling, J."],["dc.contributor.author","Slotta, J. E."],["dc.contributor.author","Kollmar, O."],["dc.contributor.author","Schilling, M. K."],["dc.contributor.author","Menger, M. D."],["dc.contributor.author","Richter, S."],["dc.date.accessioned","2019-07-09T11:40:02Z"],["dc.date.available","2019-07-09T11:40:02Z"],["dc.date.issued","2012"],["dc.description.abstract","BACKGROUND: Hepatic arterial infusion (HAI) has been developed for high-dose regional chemotherapy of unresectable liver metastases or primary liver malignancies. While it is well known that high concentrations of tumor necrosis factor (TNF)-α damage tumor blood perfusion, there is no information on whether autochthonous liver perfusion is affected by HAI with TNF-α. Therefore, we investigated the effects of HAI with TNF-α on hepatic macro- and microvascular perfusion. METHODS: Swabian Hall pigs were randomized into three groups. HAI was performed with either 20 or 40 µg/kg body weight TNF-α (n = 6 each group). Saline-treated animals served as controls (n = 6). Analyses during a 2-hour post-HAI observation period included systemic hemodynamics, portal venous and hepatic arterial blood flow, portal venous pressure, and the blood flow in the hepatic microcirculation. RESULTS: HAI with TNF-α caused a slight decrease of mean arterial blood pressure (p < 0.001), which was compensated by a moderate increase of heart rate (p < 0.001). No further systemic side effects of TNF-α were observed. HAI with TNF-α further caused a slight but not significant decrease of portal venous blood flow (p = 0.737) in both experimental groups, paralleled by an increase of hepatic arterial blood flow (p = 0.023, 20 µg/kg; p = 0.034, 40 µg/kg) resulting in an overall hepatic hyperperfusion. The hepatic hyperperfusion after HAI with 20 µg/kg TNF-α was more pronounced and associated with a 40% decrease of the blood flow in the hepatic microcirculation (p = 0.009). HAI with 40 µg/kg TNF-α was only associated with a temporary and moderate total hepatic hyperperfusion and did not affect the blood flow in the hepatic microcirculation. CONCLUSION: HAI with TNF-α causes a decrease of portal venous flow; however, this is overcompensated by an increased hepatic arterial blood flow, resulting in a total hepatic hyperperfusion. Moderate total hepatic hyperperfusion does not affect the blood flow in the hepatic microcirculation, while a persistent and more pronounced hyperperfusion may cause hepatic microcirculatory disturbances."],["dc.identifier.doi","10.1159/000339306"],["dc.identifier.fs","594196"],["dc.identifier.pmid","22739241"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10601"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58078"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1421-9921"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.mesh","Animals"],["dc.subject.mesh","Blood Pressure"],["dc.subject.mesh","Female"],["dc.subject.mesh","Heart Rate"],["dc.subject.mesh","Hepatic Artery"],["dc.subject.mesh","Liver Circulation"],["dc.subject.mesh","Male"],["dc.subject.mesh","Microcirculation"],["dc.subject.mesh","Portal Vein"],["dc.subject.mesh","Swine"],["dc.subject.mesh","Tumor Necrosis Factor-alpha"],["dc.subject.mesh","Venous Pressure"],["dc.title","Hepatic arterial infusion with tumor necrosis factor-α induces early hepatic hyperperfusion."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1267"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"],["dc.bibliographiccitation.lastpage","1282"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Adam, R."],["dc.contributor.author","Karam, V."],["dc.contributor.author","Delvart, V."],["dc.contributor.author","Trunečka, P."],["dc.contributor.author","Samuel, D."],["dc.contributor.author","Bechstein, W. O."],["dc.contributor.author","Němec, P."],["dc.contributor.author","Tisone, G."],["dc.contributor.author","Klempnauer, J."],["dc.contributor.author","Rossi, M."],["dc.contributor.author","Rummo, O. O."],["dc.contributor.author","Dokmak, S."],["dc.contributor.author","Krawczyk, M."],["dc.contributor.author","Pratschke, J."],["dc.contributor.author","Kollmar, O."],["dc.contributor.author","Boudjema, K."],["dc.contributor.author","Colledan, M."],["dc.contributor.author","Ericzon, B. G."],["dc.contributor.author","Mantion, G."],["dc.contributor.author","Baccarani, U."],["dc.contributor.author","Neuhaus, P."],["dc.contributor.author","Paul, A."],["dc.contributor.author","Bachellier, P."],["dc.contributor.author","Zamboni, F."],["dc.contributor.author","Hanvesakul, R."],["dc.contributor.author","Muiesan, P."],["dc.date.accessioned","2019-07-09T11:42:14Z"],["dc.date.available","2019-07-09T11:42:14Z"],["dc.date.issued","2015-05-01"],["dc.description.abstract","This study was a retrospective analysis of the European Liver Transplant Registry (ELTR) performed to compare long-term outcomes with prolonged-release tacrolimus versus tacrolimus BD in liver transplantation (January 2008-December 2012). Clinical efficacy measures included univariate and multivariate analyses of risk factors influencing graft and patient survival at 3 years posttransplant. Efficacy measures were repeated using propensity score-matching for baseline demographics. Patients with <1 month of follow-up were excluded from the analyses. In total, 4367 patients (prolonged-release tacrolimus: n = 528; BD: n = 3839) from 21 European centers were included. Tacrolimus BD treatment was significantly associated with inferior graft (risk ratio: 1.81; p = 0.001) and patient survival (risk ratio: 1.72; p = 0.004) in multivariate analyses. Similar analyses performed on the propensity score-matched patients confirmed the significant survival advantages observed in the prolonged-release tacrolimus- versus tacrolimus BD-treated group. This large retrospective analysis from the ELTR identified significant improvements in long-term graft and patient survival in patients treated with prolonged-release tacrolimus versus tacrolimus BD in primary liver transplant recipients over 3 years of treatment. However, as with any retrospective registry evaluation, there are a number of limitations that should be considered when interpreting these data."],["dc.identifier.doi","10.1111/ajt.13171"],["dc.identifier.pmid","25703527"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13121"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58624"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1600-6143"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.mesh","Adult"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Europe"],["dc.subject.mesh","Female"],["dc.subject.mesh","Graft Rejection"],["dc.subject.mesh","Graft Survival"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Immunosuppressive Agents"],["dc.subject.mesh","Immunotherapy"],["dc.subject.mesh","Kaplan-Meier Estimate"],["dc.subject.mesh","Liver Failure"],["dc.subject.mesh","Liver Transplantation"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Multivariate Analysis"],["dc.subject.mesh","Registries"],["dc.subject.mesh","Retrospective Studies"],["dc.subject.mesh","Risk Factors"],["dc.subject.mesh","Tacrolimus"],["dc.subject.mesh","Treatment Outcome"],["dc.title","Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]